The immunity protein to colicin A (Cai), which is constitutively expressed at a very low level in Escherichia coli strains, has been studied in recombinant plasmid constructs allowing expression of various immunity fusion proteins under the control of inducible promoters. The 13-amino acid NH2-terminal region of Cai was substituted by polypeptides from 13-galactosidase or from colicin A. Upon induction of the chimeric proteins, the rate of expression of the immunity protein could be correlated to the level of resistance to colicin A. The immunity protein has been "tagged" with an epitope from the colicin A protein for which a monoclonal antibody is available. Using this technique, we have directly demonstrated that the immunity protein is located in the cytoplasmic membrane. The results indicate that the NH2-terminal region of Cai is directed toward the cytoplasm and is probably not required for Cai insertion into the membrane or for its function.
Colicinogenic plasmids confer upon their host strains the ability to produce a bacteriocin and the property of being insensitive (immune) to this toxin. Colicins A, El, K, Ta, and Tb are known to kill sensitive bacteria by forming voltagedependent ion channels (1) (2) (3) (4) (5) (6) .
Various groups are now trying to elucidate how cells producing channel-forming colicins are able to protect themselves specifically against the colicin they produce while remaining sensitive to heterologous colicins with identical modes of action. The best-documented example of this specificity is provided by colicins Ta and Tb, which are structurally related (7) , and which adsorb to a common outer membrane receptor (8) , yet differ in immune specificity.
Cellular immunity to colicins Ta or Tb does not affect affinity for the receptors (9) . The immunity proteins for various channel-forming colicins have been shown to reside in the cytoplasmic membrane (10, 11) where the interaction between immunity protein and the corresponding colicin is assumed to occur.
The nucleotide sequence of the gene for the immunity protein to colicin A has been determined (12) . The immunity protein (178 amino acids) is expressed constitutively at a low level. The cai gene encoding this protein is located in the intercistronic region between caa and cal, the colicin and lysis protein structural genes, and is transcribed in the opposite direction. As a consequence, cai transcription is turned off when the caa-cal operon is induced (13) . We have demonstrated that this immunity protein is required to protect the cells only against the effects of external colicin A (14) , presumably because colicin in the cytoplasm cannot function correctly since the polarity of the transmembrane energy potential is opposite that required for channel formation (15) . A different result has been reported for colicin El (16) . This may be due to a difference in electrophysiological properties between the two colicins (17) (18) (19) .
For colicin El (20) and colicins Ta and lb (7) , it has been demonstrated that the information necessary for immunity recognition resides in the COOH-terminal domain of the colicin proteins. Since this is the pore-forming domain for all depolarizing colicins (1), it is likely that such a situation holds true for colicin A as well.
The studies reported here provide strains producing recombinant immunity proteins that are inducible. Induction kinetics showed a correlation between the rate of expression of chimeric immunity proteins and the occurrence of the immunity function. It is also demonstrated, using a monoclonal antibody directed against the NH2-terminal region of a colicin A-immunity recombinant protein, that the immunity protein is located in the cytoplasmic membrane.
The constructs that are described should allow us to probe the topology of the polypeptide chain in this membrane. They have provided evidence that the 13-amino acid NH2-terminal region of Cai is directed to the cytoplasm and is neither required for insertion into the membrane nor for function. In addition, we have shown that a f-galactosidase-immunity chimeric protein in which the immunity portion is located in the COOH-terminal region of /3-galactosidase is not inserted into the cytoplasmic membrane but instead aggregates in the cytoplasm.
MATERIALS AND METHODS
Bacterial Strains, Growth Conditions, and Plasmids. Escherichia coli K-12 strains W3110 nai (21) , BMH 71-18 Aprolac F'laClqZA M15pro+ (22) , and AD21 A pro-lac thi cya 283 F'lac qZAM15Y'pro+ (23) 
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percentage of survival was expressed as the ratio of the absorbance (at 600 nm) of the sample incubated with colicin A to that of the control sample incubated with the dilution buffer (10 mM sodium phosphate, pH 6.8/0.5 mg of bovine serum albumin per ml) (24) . Electron Microscopy. The procedure for fixation, embedding, and cryoultramicrotomy has been described (25) . The vesicles shown in Fig. 7 were stained by the adsorption technique (26) using 0.1% uranyl acetate and 0.8% methyl cellulose for 5 min on ice.
NaDodSO4/Polyacrylamide Gel Electrophoresis and Immunoblotting. Protein analysis was carried out on 12.5% polyacrylamide gels. The electrophoretic transfer of proteins to nitrocellulose and their immunological detection were carried out as described (27) . To detect the constructs containing the 178-residue NH2-terminal region of colicin A, the monoclonal antibody 1Cl1 (28) and peroxidase-conjugated anti-mouse antibody were used.
Ceil Fractionation and Separation of Inner and Outer Membranes. Envelopes were prepared from osmotically lysed spheroplasts and separated into inner and outer membranes by sucrose-density gradient centrifugation as described (29) .
Trypsin Treatment of Vesicles. Vesicles were prepared as described (29) . Trypsin treatment of vesicles from the light sucrose gradient fraction was carried out as described (30) . The samples were then solubilized and subjected to immunoblot analysis.
RESULTS
Constructions of fi-Galactosidase-Immunity Protein Fusions. The plasmid IMM10 as well as the replicative form RFE2, which carry the entire cai gene, have been described (14, 25) (31) . Then, the Bgl II/Pst I fragment of RFE2 was exchanged with that of pUR29OC1 to reconstitute an almost entire cai gene (Fig. 1) . The E22 chimeric protein obtained is described in Fig. 2 . It contains the 1025 amino acid residues of f3-galactosidase fused to Cai at amino acid residue 14.
Upon induction with IPTG, the fusion protein was found to be expressed at a high level. We found that the chimeric protein and the f3-galactosidase activity were associated with the particulate fraction. However, no difference was observed with regard to colicin A sensitivity in induced or noninduced cells (Table 1 ). This result was readily explained when the localization of the chimeric protein was determined by ImmunoGold labeling of cryosections incubated with anti-13-galactosidase antiserum. Large aggregates corresponding to the chimeric protein and its proteolysis products were detected in the cytoplasm after ImmunoGold labeling (Fig. 3) . The very large f-galactosidase polypeptide chain in the fusion protein was apparently correctly folded since it possessed enzyme activity.
In another construction, the Pst I/BamHI fragment of pUR290E22 was inserted into pUC12 ( Fig. 1) NaDodSO4/polyacrylamide gel electrophoresis. We were only able to characterize the VG4 protein in a cell-free coupled transcription-translation system. The hybrid protein might be unstable and rapidly degraded by proteolytic enzymes prior to its insertion into the membrane as suggested by in vitro synthesis results, since polypeptides of lower molecular weight than VG4 were detected in large amounts (data not shown).
Replacement of the Amino-Terminal Region of Cai by That of Colicin A. The results presented above suggested that the amino-terminal region of Cai (12 residues) is not necessary for its protective function. To further investigate this point, another construct involving replacement of its amino terminus was made. The Sac I/Pvu II fragment of pVG4 was exchanged with the Sac I/EcoRV fragment of pColA9 to yield pVJ4 (Fig. 1) . This Cai fusion protein has the 16 amino-terminal acid residues of colicin A plus 4 amino acids from p-galactosidase fused to amino acid 13 of Cai (Fig. 2) . The expression of this fusion protein was under the control of the mitomycin C-inducible caa gene promoter-operator region (13, 32) . In the absence of inducer, the repression by LexA prevented cells containing pVJ4 from expressing immunity to colicin A (Table 1) .
In contrast, after induction with mitomycin C (300 ng/ml), these cells became insensitive to the colicin action (Table 1) . The results described above provided strong evidence that the amino-terminal region of Cai could be replaced by some soluble polypeptide tail while preserving the immunity function.
Immunodetection of the Immunity Protein Containing a Soluble Polypeptide Tail in Its Amino-Terminal Region. Many monoclonal antibodies directed against colicin A have been obtained (28) . One of them, 1C11, is directed against an epitope located in the first 70 amino acids of the colicin A. To obtain a hybrid protein allowing an overproduction of Cai as well as antibody detection, the EcoRI/Ava I fragment of pColA9 was exchanged with the Sma I/EcoRI fragment of pVJ4 (Fig. 1) . The protein constructed contained the first 178 NH2-terminal residues of colicin A with three additional amino acids fused to amino acid 13 of Cai (Fig. 2) . W3110 cells transformed with pVL1 were insensitive to the action of colicin A only after induction of the VL1 protein with mitomycin C (Table 1) . Furthermore, the acquisition of immunity of the cells to colicin A was correlated with the expression of the protein in a time dependent manner. A protein of the expected molecular weight was produced by the induced cells and reacted with the monoclonal antibody 1C11 (Fig. 4) . The protein was detectable by 30 min after induction and increased to a maximum at 150 min. Although the amount of VL1 did not increase between 150 and 240 min, the percentage of surviving cells was higher at 240 min (Fig. 5) . It is likely that a significant fraction of VL1 is degraded prior to its insertion into the membrane and that a very low amount of Cai is sufficient for the protective function.
Localization of the Immunity Protein. Although we had previously suggested that Cai was localized in the cytoplasmic membrane, direct evidence for this has never been obtained. We prepared envelopes of induced W3110 (pVL1) cells and the inner and outer membranes were separated by centrifugation on sucrose gradient (29) . Fractions of the gradient were then electrophoresed and immunoblotted with the monoclonal antibodies 1C11. The fusion protein was found almost entirely in the lower density fractions corresponding to the inner membrane, with very little in the higher density fraction containing ompF and other outer membrane proteins (Fig. 6 ). In addition, VL1 could be extracted from the cell envelope by Triton X-100 (data not shown) under conditions that have been observed to prefer- Biochemistry: Geli et al. entially solubilize cytoplasmic membrane proteins (33) . However, we have not been able to visualize this fusion protein by ImmunoGold labeling, probably because it was below the detection level in ultrathin sections of frozen cells.
The NH2-Termibal "Tag" of the Fusion Immunity Protein Is Directed Toward the Cytoplasm. The first 178 residues in the NH2-terminal region in the fusion protein VL1 were rather hydrophilic, and therefore we assumed they would be accessible to proteases if properly exposed. To probe the topology of VL1, right-side-out vesicles of inner membranes containing VL1 were subjected to the proteolytic action of trypsin. These vesicles were sealed as shown by electron microscopy and the hydrophilic polypeptide tag was not accessible to trypsin (Fig. 7) . In contrast, after the addition of Triton X-100, which disrupted the vesicle integrity, the NH2-terminal portion was digested by trypsin and therefore the protein was no longer detected by immunoblot analysis. When the vesicles were incubated with Triton X-100 only, it promoted the activation of endogenous membrane proteases as reported (30) , which partly digested the polypeptide tag. These results demonstrated that the hydrophilic portion of protein VL1 was protected in sealed vesicles and thus located at the inner face of the cytoplasmic membrane.
CONCLUSION
Although the mechanism of immunity is not known, the results described here clearly demonstrate that Cai must be inserted into the cytoplasmic membrane to-confer immunity. The overproduction of hybrid immunity proteins is not lethal for the cells; however, the overproduced immunity fusion proteins are rapidly degraded. Despite this fact, the insertion of a low amount of these proteins in the cytoplasmic membrane is apparently sufficient to confer immunity to the cells. The results presented here also demonstrate that the nature of the amino-terminal tail for this integral membrane protein does not influence its insertion into the membrane. It is of interest that fusion of a relatively hydrophilic portion of the colicin A molecule (representing half of the fusion protein) to the immunity protein changes its localization from cytoplasm (25) to membrane. The insertion of this protein, which contains 4 putative membrane-spanning segments (14) , might be determined either by a succession of "start" and "stop" signals as proposed by Blobel (34) or by a mechanism in which neighboring hydrophobic segments pair up and penetrate the membrane as helical hairpins (35) . Our study does not directly address this point but, apart from the E22 protein, all of the other constructs can be functionally inserted into the membrane, although we do not know the efficiency of this process. The 14-amino acid NH2-terminal region of the Cai polypeptide chain can be changed or extended without any dramatic effect on the function of Cai, even if the efficiency of insertion into the membrane and the stability of the protein might be affected by the substitution of the NH2-terminal region. This region is thus not necessary for the insertion mechanism, in strong contrast to the role played by NH2-terminal sequences in precursor forms of exported proteins (36, 37) .
The grafting of a foreign epitope to the minor Cai protein, which had until now escaped detection, allowed us to follow the synthesis and to determine the location of the hybrid protein. With the availability of monoclonal antibodies directed against known epitopes, this technique of using an epitope as a tag to label a protein should prove useful for many purposes. By using this technique, the VL1 protein has been purified by immunoadsorbent chromatography and reconstituted into liposomes. Its insertion in the vesicles was then probed by electron microscopy using the monoclonal antibody lC11 and gold-coated protein A (V.G., A. Bernadac, M. Knibiehler, and C. L., unpublished data).
